Tg Therapeutics shares fall 1.06% after-hours as clinical trial updates and legal risks weigh on sentiment.

Tg Therapeutics, Inc. fell 1.06% in after-hours trading. The company's stock price decline may be attributed to the ongoing legal risks and the anticipation of future clinical trial data presentations. The company's CASGEVY® program has achieved its target goal with over 75 authorized treatment centers activated globally and approximately 115 patients having had cells collected across all regions. Additionally, clinical trials for CTX310™, CTX320™, CTX112™, and CTX131™ are ongoing, with updates expected in the coming years.